Equities research analysts expect Vericel Corp (NASDAQ:VCEL) to report ($0.01) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Vericel’s earnings. The lowest EPS estimate is ($0.03) and the highest is $0.01. Vericel posted earnings of ($0.02) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The firm is scheduled to report its next earnings report on Tuesday, November 5th.
On average, analysts expect that Vericel will report full-year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.28). For the next year, analysts expect that the business will report earnings of $0.30 per share, with EPS estimates ranging from $0.20 to $0.37. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Vericel.
Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.42. The company had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $24.13 million. Vericel had a negative return on equity of 0.99% and a negative net margin of 18.14%. Vericel’s revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.12) EPS.
NASDAQ VCEL opened at $16.55 on Friday. The firm has a market capitalization of $728.31 million, a P/E ratio of -118.21 and a beta of 2.75. The business has a fifty day simple moving average of $18.22 and a 200 day simple moving average of $17.92. Vericel has a 12 month low of $10.51 and a 12 month high of $21.00. The company has a current ratio of 7.50, a quick ratio of 7.12 and a debt-to-equity ratio of 0.28.
In other news, CFO Gerard J. Michel sold 17,500 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $15.62, for a total transaction of $273,350.00. Following the completion of the transaction, the chief financial officer now owns 131,422 shares in the company, valued at approximately $2,052,811.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Gerard J. Michel sold 17,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $16.62, for a total value of $282,540.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,500 shares of company stock valued at $890,450. Insiders own 4.50% of the company’s stock.
Several hedge funds have recently bought and sold shares of VCEL. Advisory Services Network LLC boosted its position in shares of Vericel by 1,400.0% during the 1st quarter. Advisory Services Network LLC now owns 1,500 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 1,400 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Vericel by 665.8% during the 2nd quarter. Royal Bank of Canada now owns 1,547 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,345 shares in the last quarter. Advisor Group Inc. increased its stake in Vericel by 152.1% in the 2nd quarter. Advisor Group Inc. now owns 2,652 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 1,600 shares during the period. Aperio Group LLC purchased a new position in Vericel in the 2nd quarter worth approximately $67,000. Finally, Pearl River Capital LLC purchased a new position in Vericel in the 1st quarter worth approximately $72,000. Institutional investors own 90.78% of the company’s stock.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
See Also: Cost of Equity For A Business, Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.